Drops of Fatty Acid Curb Symptoms of Dry Ey...(ethod by which this common condition is ...),Health
Navigation Links
Drops of Fatty Acid Curb Symptoms of Dry Eye Syndrome
Date:2/13/2008
ethod by which this common condition is treated," Dana said.
The study received funding from Johnson & Johnson Vision Care Inc.
More information
The U.S. National Library of Medicine has more about dry eye syndrome.
-- Robert Preidt
SOURCE: Harvard Medical School, news release, Feb. 11, 2008
'/>"/>
| Copyright©2008 ScoutNews,LLC. All rights reserved |
Related medicine news :
1. New buffer resists pH change, even as temperature drops
2. Over-the-counter eardrops may cause hearing loss or damage
3. Over-the-counter eardrops may cause hearing loss or damage
4. Diet Change Can Curb Fatty Liver Disease
5. Attenuation of NASH by stimulation of free fatty acid metabolism
6. New treatment effective in counteracting cocaine-induced symptoms
7. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
8. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
9. New study: Pine bark reduces perimenopausal symptoms
10. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
11. Clean to Ease Allergy and Asthma Symptoms
Post Your Comments:
Related Image:
 Drops of Fatty Acid Curb Symptoms of Dry Eye Syndrome |
Breaking Medicine News(10 mins):Health News:Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2Health News:Molecule Discovery Might Help ALS Patients 2Health News:Swine Flu Has Infected 1 in 6 Americans: CDC 2Health News:Swine Flu Has Infected 1 in 6 Americans: CDC 3Health News:Macomb County Announces New Location for Four Upcoming H1N1 Clinics 2
[1] Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting[0] Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health[0] Molecule Discovery Might Help ALS Patients[0] Swine Flu Has Infected 1 in 6 Americans: CDC[0] Macomb County Announces New Location for Four Upcoming H1N1 Clinics
Other Medicine News:Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 2Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 3Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 4Health News:Garry W. Rogerson Elected Chairman of the Board of Varian, Inc. 2Health News:Smokers Will Stop for Their Pet's Sake 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 3Health News:Diseased Heart Valve Replaced Through Small Chest Incision 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 2Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 3Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 5Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 6Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 7Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 8Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 9Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 10Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 11Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 12Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2
Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and SwedenGarry W. Rogerson Elected Chairman of the Board of Varian, Inc.Smokers Will Stop for Their Pet's SakeDiseased Heart Valve Replaced Through Small Chest IncisionThe LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to StockholdersShaklee Hits the Road with its Infinite Possibilities Tour in New York, NY
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Within3 Expands into Mobile Applications 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 1Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 4Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 1Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 2Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 3Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 4
Other Medicine Technology:Reaction to Avandia Warnings Stronger Among Internists Than,Endocrinologists, According to Study by GfK Market Measures 2Reaction to Avandia Warnings Stronger Among Internists Than,Endocrinologists, According to Study by GfK Market Measures 3Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |